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Abstract
Background: U.S. cancer screening guidelines communicate important information regarding the
ages for which screening tests are appropriate. Little attention has been given to whether breast,
colorectal and prostate cancer screening test use is responsive to guideline age information
regarding the age of screening initiation.
Methods: The 2006 Behavioral Risk Factor Social Survey and the 2003 National Health Interview
Surveys were used to compute breast, colorectal and prostate cancer screening test rates by single
year of age. Graphical and logistic regression analyses were used to compare screening rates for
individuals close to and on either side of the guideline recommended screening initiation ages.
Results: We identified large discrete shifts in the use of screening tests precisely at the ages where
guidelines recommend that screening begin. Mammography screening in the last year increased
from 22% [95% CI = 20, 25] at age 39 to 36% [95% CI = 33, 39] at age 40 and 47% [95% CI = 44,
51] at age 41. Adherence to the colorectal cancer screening guidelines within the last year
increased from 18% [95% CI = 15, 22] at age 49 to 19% [95% CI = 15, 23] at age 50 and 34% [95%
CI = 28, 39] at age 51. Prostate specific antigen screening in the last year increased from 28% [95%
CI = 25, 31] at age 49 to 33% [95% CI = 29, 36] and 42% [95% CI = 38, 46] at ages 50 and 51. These
results are robust to multivariate analyses that adjust for age, sex, income, education, marital status
and health insurance status.
Conclusion: The results from this study suggest that cancer screening test utilization is consistent
with guideline age information regarding the age of screening initiation. Screening test and
adherence rates increased by approximately 100% at the breast and colorectal cancer guideline
recommended ages compared to only a 50% increase in the screening test rate for prostate cancer
screening. Since information regarding the age of cancer screening initiation varies across countries,
results from this study also potentially have implications for cross-country comparisons of cancer
incidence and survival statistics.
Background
Cancer screening tests are available for detecting breast,
colorectal, and prostate cancers. Ideally, cancer screening
tests detect cancer at an early stage when medical treat-
ment increases the probability of survival. However,
screening tests also generate false positives that may lead
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to the use of more invasive procedures. For breast cancer,
randomized control trials and observational studies show
that mammography screening reduces mortality [1,2]. A
recent compendium of micro-simulation modeling stud-
ies has produced a lower bound estimate of 28% for the
role of mammography screening in reducing U.S. breast
cancer mortality over the 1975-2000 time period[2]. Ran-
domized control trials also show that the fecal occult
blood test (FOBT) reduces colorectal cancer mortality by
16% [3]. Randomized control trial evidence on the health
benefits from the use of the PSA screening test has only
recently become available [4,5]. The European trial [5]
found a 20% reduction in mortality (9 year median follow
up) from PSA screening but the U.S. trial [4] did not find
any differences in 7 to 10 year mortality between the treat-
ment and control groups.
Due to the complicated tradeoffs involved in the use of
these screening tests, several organizations, including the
American College of Physicians, American Urological
Association, American College of Radiology, American
Cancer Society (ACS), and the United States Preventive
Services Task Force (USPSTF), have published guidelines
to aid patient and physician decision-making. These
guidelines generally contain recommendations on
whether individuals should be screened for a specific can-
cer, the test to be used, the frequency with which individ-
uals should be screened (e.g., annually, biennially, every
five years), and importantly the age at which screening test
use should start.
While many organizations publish cancer screening
guidelines, in the United States, the guidelines published
by the ACS and the USPSTF represent the vast majority of
the recommendations from these other organizations.
Table 1 presents the ACS and USPSTF cancer screening test
guidelines for asymptomatic individuals. These guidelines
were in effect during 2003 for colorectal cancer screening
and 2006 for breast and prostate cancer screening--the
years of the data used in the analyses in this paper [6-9].
In 2006, both the ACS and the USPSTF recommended
that annual mammography screening for breast cancer
begin at age 40 and that colorectal cancer screening for
men and women start at age 50. Neither organization
specifies the screening test that should be used to screen
for colorectal cancer. In the case of prostate cancer, the rec-
ommendations from the two organizations differ. The
ACS recommends that physicians offer the prostate spe-
cific antigen (PSA) test annually to individuals starting at
age 50, while the USPSTF finds insufficient evidence to
determine whether individuals should receive the PSA
test. In this instance, the ACS favors shared decision-mak-
ing between the physician and patient with respect to PSA
screening [10].
An extensive academic literature has examined the use of
screening tests in the ages recommended by the guidelines
[11-26]. A recent paper by Smith et al. (2007) [26] uses
the 2004 Behavioral Risk Factor Surveillance System
(BRFSS) data to evaluate screening rates. They find that
58% of women ages 50-64 received a mammogram
Table 1: Cancer Screening Test Guidelines for Asymptomatic Populations (Effective 2003 for Colorectal Cancer and 2006 for Breast 
and Prostate Cancers)
Panel A: Colorectal Cancer Screening American Cancer Society (2001): - Annual fecal occult blood test ages 50+
- Or sigmoidoscopy every 5 years starting at age 
50
- Or annual FOBT and flex. Sig. Every 5 years 
starting at 50
- Colonoscopy every 10 years starting at age 50
- Double contrast barium enema every 5 years 
starting at 50
United States Preventive Services Task Force 
(2001-2004):
- Screening recommended ages 50+
- Annual fecal occult blood test and or periodic 
sigmoidoscopy
Panel B: Prostate Cancer Screening American Cancer Society (2004): - Prostate specific antigen test offered annually to 
men ages 50+ with 10+ years life expectancy
United States Preventive Services Task Force 
(2005):
- Insufficient evidence to recommend or not 
recommend the test
Panel C: Breast Cancer Screening American Cancer Society (2004): - Annual mammography ages 40+
United States Preventive Services Task Force 
(2005):
- Mammography every 1-2 years ages 40+
Source: ACS Guidelines, Smith et al. (2004). aUSPSTF 2002 (For Colorectal Cancer Screening). bUSPSTF 2002 (For Prostate Cancer Screening) 
cUSPSTF 2002 (For Breast Cancer Screening)BMC Health Services Research 2009, 9:185 http://www.biomedcentral.com/1472-6963/9/185
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within the previous year, 52% of women and men ages
50-64 received either a home FOBT within the past year
year or a sigmoidoscopy or a colonoscopy within the past
5 years, and 54% of men ages 50-64 received a PSA test
within the previous year.
We extend this line of research by explicitly evaluating
whether breast, colorectal, and prostate cancer screening
test rates are consistent with guideline age information. By
recommending an age to start screening, guidelines imply
that screening is more valuable for individuals of a certain
age. Given that physicians report adhering to cancer
screening guidelines [13,27] and state health insurance
mandates based on the ACS and USPSTF guidelines
reduce the price of screening tests [28], a key yet unex-
plored question in this literature then becomes whether
screening test behavior is responsive to guideline age rec-
ommendations. This question of age appropriate screen-
ing is studied by evaluating breast, colorectal and prostate
cancer screening test rates for individuals close to and on
either side of the guideline recommended ages. A simulta-
neous evaluation of the breast, colorectal and prostate
cancer screening will also provide insight into whether
physician and patient response is related to differences in
the ACS and USPSTF recommendations. As noted above,
for breast and colorectal cancer screening there is agree-
ment across the ACS and USPSTF guidelines that asymp-
tomatic individuals should receive the test. In the case of
the PSA test, there is no agreement across the guidelines
that the test should be utilized, and the ACS recommen-
dation is weaker in that it only requires an offer of the test.
Methods
Data Source
The following analyses were conducted using data from
the 2006 BRFSS and the 2003 National Health Interview
Survey (NHIS) sample adult file [29,30]. Both the BRFSS
and the NHIS collect information on demographics,
health, and health care use of the non-institutionalized
U.S. population. Both are annual surveys, use stratified
sampling methods for data collection and are designed to
provide estimates that are representative of the U.S. non-
institutionalized population. Individuals of all ages are
eligible to be sampled in the NHIS but the BRFSS prima-
rily samples individuals 18 years and older. Most impor-
tantly, the surveys include information on adult cancer
screening test use and the timing of the last cancer screen-
ing test, i.e., whether the screening occurred within the
past year, two years, or further back. More documentation
about the design of the surveys is available at the BRFSS
and NHIS data sites [29,30].
Breast cancer screening test data for women aged 30-70
and prostate cancer screening test data for men aged 40-70
is taken from the 2006 BRFSS. The colorectal cancer
screening test data for men and women aged 40-70 is
from the 2003 NHIS. The NHIS data is analyzed in con-
junction with the BRFSS data because the BRFSS only col-
lects colorectal cancer screening test information for men
and women ages 50 and older. Reporting for screening
test use is extremely high in these surveys. In the BRFSS,
97% of women aged 30-70 (N = 153,606) and 92% of
men aged 40-70 (N = 75,285) report their mammography
and PSA screening test behavior. In the NHIS, 95% of
adults aged 40-70 (N = 13,991) years report on their
colorectal cancer screening test behavior.
Outcomes
For breast cancer we calculated the proportion of women
who received a mammogram in the past 1 and 2 years. For
colorectal cancer the USPSTF and the ACS specify annual
FOBT use and that the FOBT sample be collected at home.
Guidelines also recommend either sigmoidoscopy use
once every 5 years or colonoscopy use once every 10 years.
Neither guideline takes a stance on which colorectal
screening test to perform. Consequently, we consider
someone as adherent with the colorectal cancer screening
guidelines if they received either a home FOBT in the last
year, a sigmoidoscopy in the last 5 years or a colonoscopy
in the last 10 years. We also evaluated the share of individ-
uals who received either a home FOBT within the last 2
years, a sigmoidoscopy within the last 5 years or a colon-
oscopy within the last 10 years. For prostate cancer we cal-
culated the share of men who received a PSA screening test
in the past 1 and 2 years.
Analytic Strategy
In evaluating whether screening test use is consistent with
guideline age information, we examined screening rates at
the age thresholds where guidelines recommend that
screening begin. If screening rates are consistent with
guideline age information then one would expect to see a
large, discrete increase in screening precisely at the guide-
line recommended screening initiation ages. Within this
framework, even if screening rates at the recommended
age thresholds are high, a finding that screening rates right
below the recommended ages are equivalent would sug-
gest that screening utilization is not consistent with guide-
line age information. These results would suggest the
simpler explanation that all individuals receive the same
amount of screening and that age information contained
in guidelines is not related to individual or physician deci-
sion-making. Similarly, even if screening rates at the rec-
ommended ages are low, screening patterns can still be
consistent with guideline age information. For example,
even if the colorectal cancer-screening rate is only 30% at
the recommended ages, it is possible for screening to be
responsive to guideline age information if the data show
that the colorectal screening rate just below the recom-
mended ages is only 15%. This change in screening pre-BMC Health Services Research 2009, 9:185 http://www.biomedcentral.com/1472-6963/9/185
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cisely at the guideline recommended ages would imply
that colorectal cancer screening use at the recommended
age threshold increased by 100%.
In the following analyses, we first provide graphical evi-
dence with respect to the relationship between age and
breast, colorectal and prostate cancer screening test rates.
We then formalize the analytic strategy in the regression
framework by fitting the following logistic regression
model, Pr [Y  = 1] = B1(age) +B2 (guideline)  where the
dependent variable is utilization of breast, colorectal and
prostate cancer screening tests.
In this specification, "age" is a linear variable, while the
"guideline" variable is a dummy variable that assumes a
value of 1 if the individual is within the guideline recom-
mended ages for that screening test and zero otherwise.
The B1 coefficient estimates how screening relates to age,
while the B2 coefficient estimates the change in screening
from being at an age where screening is recommended.
This analysis allows us to isolate the shift in the screening
rate that occurs for individuals within the guideline rec-
ommended ages, relative to individuals outside of the
guideline recommended ages, from the normal increase
in screening test use that occurs with age [31].
In the regression analysis, to adjust for potential con-
founding by socioeconomic and demographic variables
related to screening [15,24,32-34], we also estimated
regression models that include income, health insurance,
education, race and marital status. In these regressions,
race is defined as white or non-white. An individual is
defined as having health insurance if they are covered by
a private or public health insurance plan. Education is
grouped into four categories: less than high school, high
school graduate, some college, and college graduate or
higher (omitted regression category is "less than high
school"). We also adjust for marital status by using the fol-
lowing categories: married/partnered, divorced or sepa-
rated, widowed and never married (omitted regression
category is married/partnered). We group the BRFSS
income data in to 4 groups: < $15,000; $15,000 to
$24,999; $25,000 to 434,999; and > $35,000. In the NHIS
data, we match the BRFSS income categorizations, but due
to differences in income reporting between the NHIS and
the BRFSS we add two other dummy variables: one varia-
ble for individuals who report their annual household
income as less than $20,000, and one variable for individ-
uals who report their annual household income as greater
than $20,000.
Finally, the BRFSS and the NHIS surveys use stratified
sampling methods to collect survey information and the
results reported in this study take the survey weights and
complex sampling frames into account. All of the follow-
ing analyses were conducted in Stata Version 10.
Results
Graphical Analysis
Breast Cancer
Figure 1 is a plot, using the 2006 BRFSS data, of the share
of women who received a mammogram in the past year
and the past two years by age. In Figure 1, a large discrete
shift in the percentage of women of being screened occurs
at exactly the age that guidelines recommend that screen-
ing begin. The share of 39 year old women screened in the
last year is 22%, and this figure rises to 36% (p < .001) for
a woman who is 40 years old and 47% (p < .001) for a
woman who is 41 years old. Using the past two years as a
screening measure shows similar results. Screening rises
from 34% at age 39 to 48% (p < .001) at age 40 to 60% (p
< .001) at age 41. One issue to note regarding the differ-
ence between the age 40 and age 41 screening rates is that
not everyone who is 40 years old has been at the recom-
mended screening age for an equivalent amount of time.
This is because the screening measure used in the BRFSS is
"screened in the past year", which means that women
who turned 40 years of age close to the BRFSS interview
date have spent little time in the recommended screening
age. Consequently, the screening test rate for a 40 year-old
understates the potential response to an individual's age.
Colorectal Cancer
Figure 2 plots the share of men and women who received
either a home FOBT within the last year, a sigmoidoscopy
within the last 5 years or a colonoscopy within the last 10
years. As with mammography, there is a large increase in
colorectal cancer screening that occurs precisely at the age
specified by guidelines. Adherence to the guideline rec-
ommendations within the last year rises from 18% at age
49 to 19% (p = .865) at age 50 and 33% (p < .001) at age
51. Similar to the adherence in the last year measure, there
is an increase in the share of individuals who are adherent
within the past 2 years from 21% at age 49 to 22% (p =
Mammography Test Use within the Last 1 and 2 Years Figure 1
Mammography Test Use within the Last 1 and 2 
Years.
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.847) at age 50 and 34% (p < .001) at age 51. We also ana-
lyzed the colorectal cancer screening data separately by sex
but did not find any statistically significant differences
between the two groups with respect to changes in screen-
ing near age 50. Overall, the absolute changes in colorec-
tal screening adherence at the precise thresholds are
smaller when compared to mammography, but the rela-
tive changes are similar. In both cases the adherence meas-
ure increases by approximately 100% within two years of
the recommended age thresholds.
Prostate Cancer
Figure 3 presents data from the 2006 BRFSS on PSA
screening test use within the last year and two years by age.
The share of men screened within the past year rises by 5
percentage points, from 28% at age 49 to 33% (p = .035)
at age 50, and by 14 percentage points (p < .001) from age
49 to age 51. The share of men screened within the last
two years also increases by a significant amount, 17 per-
centage points (p < .001) from age 49 to age 51. Previous
work [14,17] has shown that PSA screening is performed
far more frequently than colorectal cancer screening.
While prostate cancer screening use is greater than color-
ectal cancer screening use for a given age, the prostate can-
cer screening changes at the guideline recommended ages
are smaller. PSA screening test use only increases by 50%
at the guideline recommended ages as compared to the
approximately 100% increases in the use of the breast and
colorectal cancer screening measures.
Regression Analysis
Table 2 presents marginal effects from logistic regression
models for breast and prostate cancer screening test use
within the last year and colorectal cancer screening guide-
line adherence within the last year. For these analyses, to
get precise guideline estimates, the sample for each regres-
sion was restricted to individuals within 10 years above
and below the age that guidelines recommend that screen-
ing start. For breast cancer (column 1), after adjusting for
the underlying trend of increased screening with age,
being in the guideline recommended ages increases the
probability of receiving a mammogram in the last year by
21% points (p < .001) relative to individuals not in the
guideline recommended ages. Similarly, for colorectal
and prostate cancers (columns 3 and 5), being in the
guideline recommended ages increases colorectal cancer
guideline adherence and PSA test use in the last year by
approximately 6.0% points (p = .009) and 6.8% points (p
< .001). For each of the screening types, the coefficient on
the linear age variable is also positive and statistically sig-
nificant (p < .001). Most importantly, the significant shifts
identified in the graphical analyses still remain for all the
screening tests even after adjusting for age trends.
Columns II, IV and VI in Table 2 adjust for potentially
important confounders such as income, health insurance,
education, race and marital status. The coefficients identi-
fied for individuals in the guideline recommended ages
are robust to the inclusion of demographic and socioeco-
nomic controls, as the guideline estimates from both
regression model specifications for all the screening meas-
ures are almost identical (row 2, Table 2). This implies
that differences in demographic and socio-economic vari-
ables, for individuals within and outside the guideline rec-
ommended ages, cannot account for the observed
screening changes.
Colorectal Cancer Test Use within the Last 1 and 2 years Figure 2
Colorectal Cancer Test Use within the Last 1 and 2 
years. Note: An individual is adherent with the colorectal 
cancer guidelines within the last year if they received either 
an FOBT within the last 1 year, a sigmoidoscopy within the 
last 5 years or a colonoscopy within the last 10 years. Adher-
ence within the last 2 years is defined in a similar manner 
except individuals may receive an FOBT within either the last 
1 or 2 years.
Colorectal Cancer Test Use (2003 NHIS)
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PSA Test Use within the Last 1 and 2 Years.
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One potential concern with the BRFSS and NHIS results is
that the cancer screening guideline recommendations are
specifically for screening asymptomatic individuals and
not meant for diagnostic purposes. In the BRFSS data it is
not possible to distinguish between diagnostic use and
routine screening, but this distinction is possible in the
NHIS data. In the NHIS data, individuals are asked
whether their most recent colorectal cancer test was per-
formed as part of a routine screen (or routine physical
exam) or for diagnostic reasons due to a specific problem.
Analysis of the NHIS reason for test data supports the
claim that the change in colorectal cancer test adherence
at age 50 is primarily driven by an increase in asympto-
Table 2: Logistic Regression Models for Breast, Prostate and Colorectal Cancer Test Use
BREAST CANCER
(Mammography Use Within 
the Last Year)
COLORECTAL CANCER
(Adherent to Guidelines Within
the Last Year)
PROSTATE CANCER
(PSA Test Use Within 
the Last Year)
Variables Unadjusted 
Marginal Effects
(95% CI)
Adjusted
Marginal Effects
(95% CI)
Unadjusted 
Marginal Effects
(95% CI)
Adjusted
Marginal Effects
(95% CI)
Unadjusted 
Marginal Effects
(95% CI)
Adjusted
Marginal Effects
(95% CI)
Age 0.022(.019,.024)** 0.022(.020,.025)** 0.017(.013,.020)** 0.017(.013,.020)** 0.021(.018,.023)** 0.021(.018,.023)**
Guideline 0.211(0.184,.238)** 0.212(.185,.238)** 0.060(.016,.104)** 0.056(.014,.100)** 0.068(.037,.100)** 0.067(.035,.099)**
Race - White+ - - -
Non-White 0.073(.055,.092)** -0.015(-.040,.010) 0.061(.021,.071)**
Health 
Insurance
- 0.162(.142,.183)** 0.141(.118,.164)** 0.157(.132,.182)**
Income ---
Inc. < $15000+
Inc. $15000
-24999 0.047(.007,.088)* -0.020(-.068,.029) - 0.021(-.073,.029)
Inc. $25000
34999 0.018(-.023,.059) -0.032(-.074,.011) - 0.016(-.067,.035)
Inc. $35,000 plus 0.061(.028,.094)** 0.016(-.022,.054) 0.025(-.021,.071)
Inc. < $20000 - 0.006(-.039,.051)
Inc. > $20000 -0.00(-.060,.059)
Marital Status - -
Married/
partnered+
Divorced
Widowed -0.007(-.028,.014) -0.001(-.025,.023) -0.035(-.060,-.009)
Never married -0.05(-.096,.0002) 0.029(-.025,.084) 0.051(-.009,.110)
-0.012(-.038,.014) -0.008(-.040,.025) -0.040(-.07, 01)**
Education ---
< High school+
High school grad. -0.006(-.046,.033) 0.093(.053,.134)** 0.055(.006,.103)*
Some college -0.002(-.041,.038) 0.111(.072,.150)** 0.095(.043,.148)**
College grad or 
higher
0.018(-.022,.058) 0.148(.107,.190)** 0.108(.058,.158)**
Sample Size 69547 69547 10127 10127 50028 50028
Source: Mammography and PSA data are from the 2006 BRFSS, Colorectal cancer test data are from the 2003 NHIS Adult Subsample, +Reference 
Category, *P < 0.05, ** P < 0.01.
Notes: Estimates are marginal effects from logistic regression models. For breast cancer, the regression sample is all women ages 30-50. For 
colorectal cancer the regression sample is all men and women ages 40-60. For prostate cancer the regression sample is all men ages 40-60. In each 
of the regressions, the "guideline'' variable assumes a value of 1 if the individual is within the guideline recommended age, and zero otherwise. 
Someone is defined as being adherent to the colorectal cancer screening guideline if they received either a FOBT within the past year, a 
sigmoidoscopy within the last 5 years or a colonoscopy within the last 10 years. BRFSS and NHIS income coding is different. The differences are 
described in the text.BMC Health Services Research 2009, 9:185 http://www.biomedcentral.com/1472-6963/9/185
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matic screening. Asymptomatic colorectal cancer screen-
ing adherence rises from 11% at age 49 to 12% (p = .354)
at age 50 and 21% (p < .001) at age 51. Estimating a logis-
tic regression model, with asymptomatic colorectal
screening adherence in the past year as the dependent var-
iable, and the other covariates from Table 2 shows that the
probability of asymptomatic screening adherence
increases by 5.9% (p < .001) points for individuals in the
guideline recommended ages. This estimate of the change
in asymptomatic screening adherence from being in the
guideline recommended age group is nearly identical to
the guideline estimate presented in column 4 of Table 2.
The result that most of the change in colorectal cancer test
adherence at the guideline recommended age threshold is
due to a change in asymptomatic colorectal cancer test use
is perhaps not surprising. This is because there are no the-
oretical or empirical reasons, either from biology or epi-
demiology, to expect that the underlying incidences of
breast, colorectal and prostate cancers increase discretely
at the guideline recommended age thresholds. Thus one
should not have expected a discrete increase in non-
asymptomatic colorectal diagnostic test use near age 50.
These asymptomatic colorectal cancer test results suggest
that the mammography and PSA guideline estimates iden-
tified in Table 2 primarily capture changes in asympto-
matic mammography and PSA test use.
Discussion
Identification of the extent to which screening test pat-
terns are consistent with guideline age information is
important since guideline age thresholds convey informa-
tion regarding the tradeoffs between screening benefits
and harms. The empirical results from the analyses of the
BRFSS and the NHIS data suggest that cancer screening
test behavior by physicians and patients is influenced by
age recommendations, although there are significant dif-
ferences in the magnitudes across the cancer types. Mam-
mography screening increases by 25 percentage points
from age 39 to age 41; this is more than a 100% increase
relative to the age 39 baseline screening rate. For colorec-
tal cancer there is a relative 90% increase in adherence
while PSA screening only increases by 50% at the guide-
line recommended ages. The larger relative increase in
mammography and colorectal cancer screening test use,
when compared to PSA screening test use, is consistent
with guideline recommendations for the use of these tests
being much stronger than the guideline recommenda-
tions for the use of the PSA test.
An important contribution of this research is the idea that
analysis of cancer screening test rates on either side of the
guideline recommended age thresholds is necessary to
understand the full impact of guideline age recommenda-
tions. Since screening is not recommended for individuals
who are younger than the guideline recommended age
thresholds, the test rates presented in this paper for indi-
viduals in these groups represent upper bound measures for
the overuse of these tests. Considering the results from
this perspective, the PSA test is potentially the most over-
used test, as 19% of men aged 40-49 received the test in
the past year. Mammography use in 30-39 year old
women is also substantial as 14% of women received this
test in the last year. Similarly, 14% of men and women
aged 40-49 also received either a FOBT in the past year, a
sigmoidoscopy in the past 5 years or colonoscopy in the
last 10 years. For colorectal cancer, only taking into
account test use for asymptomatic reasons reduces the
14% estimate of overuse to 8%.
It is necessary to note that even after crudely separating
out asymptomatic screening from total test use, these cal-
culations are likely to be strict measures of breast, prostate
and colorectal cancer screening overuse. This is because
guideline age recommendations are based primarily on
considerations regarding the tradeoffs between popula-
tion health benefits and population health costs. Guide-
lines do not take into account individual preferences for
the use of screening tests (such as risk-aversion and time
preference) [35] and do not take into account an individ-
ual's demand for health status information that is unlikely
to affect their long run health outcomes. Just as research
on screening has attempted to understand the reasons
behind low screening rates in the guideline recommended
ages [36], future research should also consider exploring
the reasons for the use of screening tests in the ages where
screening is not recommended.
Although this research has identified the extent to which
screening is consistent with guideline age recommenda-
tions, the mechanisms behind the observed increases in
screening are not well understood. Prior work has shown
that physician offer is an important predictor of screening
utilization [36] and it is likely that some combination of
an increase in physician offer of screening at the guideline
recommended ages and an increase in an individual's
demand for screening at the guideline recommended ages
explains the results identified in this study. Physician offer
and patient demand in turn are likely affected by physi-
cian and individual knowledge regarding guidelines
[13,27], responses to the coverage of screening tests at the
guideline recommended ages by insurance [28], psycho-
social factors and U.S. medical malpractice laws. The
results from this study also potentially have implications
for international comparisons of cancer incidence and
survival statistics. Compared with the United States,
guidelines for several OECD countries (for example Can-
ada and U.K) have differing recommendations with
respect to the timing of breast and prostate cancer screen-
ing [37,38]. Most notably, mammography screening isBMC Health Services Research 2009, 9:185 http://www.biomedcentral.com/1472-6963/9/185
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recommended to begin at or near age 50, the PSA test is
not recommended for asymptomatic individuals and
guidelines also recommend stopping ages for screening. If
screening rates in other OECD countries are consistent
with their own screening recommendations, then under-
standing cross-country differences in the timing of screen-
ing initiation and termination between the U.S. and other
countries can potentially aid in interpreting comparisons
of cancer incidence and survival statistics.
There are several limitations to the results identified in
this study. The most significant limitation is the inability
to distinguish between diagnostic testing and asympto-
matic screening in the case of breast and prostate cancers.
Such differentiation is possible for colorectal cancer
screening in the NHIS data but not possible for prostate
and breast cancer screening in the BRFSS data. A second
limitation is that both the BRFSS and the NHIS use self
report as the primary means of data collection and it is
possible that individuals made errors in remembering the
time frame in which they were screened or errors in
whether or not they received the test [39]. This is poten-
tially important in the case of the PSA test, a test that indi-
viduals might have trouble differentiating from a blood
test. Although there is no direct way to evaluate the mag-
nitude of these errors, it is important to note that errors in
memory and confusion would have to arise precisely at
the guideline recommended ages to explain the results
identified in this paper. We are not aware of any evidence
that suggests that errors are magnified at the guideline rec-
ommended ages.
Conclusion
This study has provided new evidence on whether breast,
colorectal and prostate cancer screening rates are respon-
sive to guideline recommendations with respect to the age
of screening initiation. The results indicate that there are
substantial increases in breast, colorectal and prostate
cancer screening precisely at the guideline recommended
ages, although little is currently known regarding the
mechanisms behind these observed increases. This
research also provides a crude upper bound estimate for
the amount of overuse of the colorectal cancer screening
tests in the ages where asymptomatic screenings are not
recommended. Future research should consider the rea-
sons why asymptomatic individuals that are outside of the
guideline recommended age thresholds receive screening
tests. The question of age appropriate screening has risen
again recently as the USPSTF guidelines now recommend
that males 75 and older not be screened with the PSA test
since the screening harms outweigh the screening benefits
for this age group [40]. Future research should also evalu-
ate the extent to which PSA screening patterns reflect this
new USPSTF age recommendation. Finally, cancer screen-
ing guideline information varies across countries. Under-
standing how this variation in guideline information
affects country screening patterns will likely aid in the
interpretation of cross-country comparisons of cancer
incidence and mortality statistics.
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